The Center for Professional Innovation & Education, Malvern, PA
January 12 & 13, 2009
Who Should Attend This course is specifically designed for personnel in the pharmaceutical and biotechnology industries and contract research organizations (CROs) who are involved in drug discovery and early drug development and who want to have a better understanding of the approaches and techniques available for discovery lead selection and optimization. Participants should have some knowledge of drug discovery and development and desire to learn more about how to logically design, conduct, and interpret lead optimization experiments in order the select the optimal compound for preclinical development. Drug discovery and development scientists, managers, and project team leaders at pharmaceutical companies and related industries will gain a detailed understanding of the types of developability assessment research studies that can be conducted to determine the drug-like attributes and potential demerits of a discovery lead or group of leads.
Learning Objectives Upon completing this course, participants will have gained the knowledge to design a logic plan of in vitro and in vivo research studies needed to evaluate the attributes and potential demerits of drug discovery leads, either small organic molecules (NCEs) or macromolecules. Participants will learn about and understand the requirements for selecting a discovery lead with a better chance of successfully completing the preclinical development effort needed to support first-in-human clinical trials.
Course Description
The content of this course will assist pharmaceutical, biotechnology, and CRO researchers and managers in understanding the requirements for a logical, well designed, and successful developability assessment or discovery lead optimization program. The various types of experiments, which include in vitro and in vivo pharmacology, stability and solubility assessments, in vitro drug metabolism and delivery, preliminary animal pharmacokinetics, and in vitro and acute toxicology, will be described and discussed. Study designs and potential results, with possible interpretations, from each of the study types will be presented. Examples of developability assessment logic plans for various types of drug discovery programs will be presented and a workshop will provide participants with the opportunity to design and discuss other logic plan types.
|
|